Aneeka Nawar Fatema

Aneeka Nawar Fatema

Auto-generated profile, based on publicly available information

Aneeka Nawar Fatema

Department of Microbiology, Prima Asia University, Dhaka 1213, Bangladesh

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Heliyon
Verified
Journal Article
Open access
AHAhmed Hossain
Ahmed Hossain
SHSaeem Arafat Hossain
Saeem Arafat Hossain
AFAneeka Nawar Fatema
Aneeka Nawar Fatema
AWAbrar Wahab
Abrar Wahab
MAMohammad Morshad Alam
Mohammad Morshad Alam
GAGias U. Ahsan
Gias U. Ahsan
In Bangladesh, treatment for urinary tract infection has become increasingly difficult due to antibiotic resistance. In addition, the prescription of age and gender-specific drugs is still far from being practiced in Bangladesh. We are examining trends of antibiotic resistance per age and gender in patients with urinary tract infection (UTI) caused by the most frequent agent, Escherichia coli. We determined the resistance of 1663 E. coli isolates obtained from urine cultures. A sensitivity study using the Kirby-Bauer method was carried out to identify the antibiotic resistance trends. Imipenem with 1.9% resistance of all isolates found to be the lowest percentage of resistance. Meropenem (2.8%), amikacin (2.8%), colistin (2.9%), and nitrofurantoin (15.8%) showed low resistance percentages. The sensitivity analysis suggests that age and gender (area under curve = 0.67) should be taken into consideration to prescribe amikacin. The increasing odds ratios (OR) by age groups suggest that amikacin is a less effective agent for older patients with UTIs. Moreover, nitrofurantoin (OR = 1.45, 95% confidence interval (CI) = 1.07-1.95) and colistin (OR = 2.09, CI = 1.13-3.76) were less effective against isolates obtained from males compared to isolates obtained from females. Meropenem was effective against bacteria obtained from all age groups and genders. On the other hand, efficacy of imipenem was lower in isolates obtained from adults older than 40 years (OR: 0.44 for < = 18 years, OR = 0.47 for 19-40 years, OR = 0.86 for 41-60 years; reference: > = 61 years). In Bangladesh, meropenem, imipenem, amikacin, colistin, and nitrofurantoin are suitable therapeutic alternatives against urinary tract pathogens. Among the oral agents, amikacin, colistin, and nitrofurantoin should be prescribed, taking consideration of age and gender. These results will assist physicians in prescribing effective primary care antibiotics for UTI patients and encouraging the implementation of health policies for a safe prescription of antibiotics.

1 November 2020 in Risk Management and Healthcare Policy
Verified
Journal Article
Open access
PDF file
NSNandeeta Samad
Nandeeta Samad
TSTemitayo Eniola Sodunke
Temitayo Eniola Sodunke
HBHasan Al Banna
Hasan Al Banna
ASAshmita Sapkota
Ashmita Sapkota
AFAneeka Nawar Fatema
Aneeka Nawar Fatema
MHMainul Haque
Mainul Haque
The world is striving against the severe crisis of the COVID-19 pandemic. Healthcare professionals are struggling to treat their patients based on nonspecific therapies. Amidst this uncertainty, convalescent plasma therapy (CPT) has appeared to be an interim adjuvant therapy for severely ill patients of COVID-19 until long-term clinical trial treatment options are available. Considering the transfusion-related hazards, especially lung injuries and microbial transmission, where sensitivity is not ensured, rigorous trials should be conducted to determine this therapy’s efficacy. Moreover, the ratio of recovered cases to plasma donors is not satisfying, which questioning this therapy’s availability and accessibility. Although some countries are making the treatment free, the attributable cost mandates a justification for its suitability and sustainability. Our article aimed to review the published facts and findings of CPT’s effectiveness in lowering the mortality rate of COVID-19. This pandemic showed that healthcare systems worldwide need core reform. A unified global collaboration must align and coordinate to face the current pandemic and enhance world readiness for future outbreaks based on health equity and equality.